Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...
Finland was the first country to offer the zoonotic avian influenza A(H5N8) vaccine manufactured by Seqirus to at-risk occupational groups following the extensive clade 2.3.4.4b A(H5N1) outbreak ...
BUFFALO, N.Y. — A vaccine under development at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work, detailed in ...
In a landmark move for the UK poultry sector, a new field trial to test highly pathogenic avian influenza (HPAI) vaccines in ...
In a phase I trial, an intranasal adjuvanted recombinant influenza vaccine appeared to result in response to a range of H5N1 clades. The adjuvanted vaccine elicited seroconversion against clade 2 ...
The Department of Health and Human Service is pulling millions of dollars in funding for a human bird flu vaccine developed by Covid vaccine-maker Moderna. "While the termination of funding from HHS ...
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced results from a ...
Since it was first detected in the United States in 2014, H5N1 avian influenza, commonly known as bird flu, has jumped from wild birds to farm animals and then to people, causing more than 70 human ...
Hosted on MSN
Seasonal flu antibodies can also target avian flu to build immunity against potential pandemic risks
Are seasonal flu antibodies also effective against avian flu? A team from the University of Geneva (UNIGE) has shown that a specific type of antibody associated with the former virus—already present ...
The rapid spread of H5N1 from wild birds to mammals, and even humans, is raising the stakes in the fight against avian influenza. As experts warn of the virus’s pandemic potential, global action on ...
NEW YORK/LONDON (Reuters) - The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results